Delivery Order SPE2DB24D3015-SPE2DB25FGAJD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $3,595.11 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a small-value transaction under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and was competitively awarded. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a delivery order valued at $14,661.49 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injectors on July 23, 2025. This firm fixed-price delivery order is non-competitive and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with completion scheduled for July 24, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,075.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 mL pen injectors on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and is being performed at the vendor's facility in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $1,143.87 and an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a continuation of the government's procurement of this diabetes medication through AmerisourceBergen's existing pharmaceutical supply contracts. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL). The contract, which represents a non-set-aside, competitively awarded delivery order with firm fixed pricing, is scheduled for ultimate completion by July 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAJDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,525.16 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on July 30, 2025. This firm fixed-price delivery order, which is not set-aside, represents a small-value transaction under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. This delivery order falls under AmerisourceBergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The DLA Medical Supply Chain utilizes this prime contract vehicle to efficiently procure medications across multiple therapeutic domains, including specialty pharmaceuticals and brand-name drugs like Zepbound, a GLP-1 receptor agonist used for weight management. The non-set-aside competitive award demonstrates the company's established capability to meet federal procurement standards through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/30/25 |